Skip to main content
. Author manuscript; available in PMC: 2016 Jun 1.
Published in final edited form as: J Endocrinol. 2015 Dec 23;228(3):R73–R83. doi: 10.1530/JOE-15-0451

Figure 3. Recovery of TGFβ1 activity emerges as a novel therapeutic target for treatment of dopamine agonist resistant prolactinomas.

Figure 3

Treatment with Thrombospondin-1 analogs (ABT-510, ABT-898) recover pituitary TGFβ1 activity, reduce tumor size, tumor angiogenesis and proliferation markers, as well as serum